Search academic texts

Information × Registration Number 0216U001136, 0113U002149 , R & D reports Title To improve the treatment of children with neuroblastoma, taking into account the biological properties of the tumor popup.stage_title Head Klymniyk Grygoriy Ivanovich, Registration Date 25-01-2016 Organization Ukrainian Research Institute of Oncology and Radiology popup.description2 Scientific report: 162 p., 40 fig. 9 Table. 7 applications, 61 source. The object of study, 228 children with neuroblastoma, 195 studies of neuroblastoma tissue samples, 283 samples of peripheral blood. Purpose - to improve the results of treatment of children with neuroblastoma, by optimizing the combined treatment methods and improve the definition of high-risk groups of patients, taking into account the biological properties of the tumor. Research methods - clinical, beam, sonographic, morphological, molecular-genetic, statistical. Equipment - histioprotsesor Histos-5, Milestone, Italy, NM325 microtome Thermo Scientific, Germany, flow tsytometometr 7500 Real-Time PCR Systems «Applied Biosystems", United States, ultrasonic apparatus ATL HDI-5000 «Philips» US. The study of molecular genetic characteristics of neuroblastoma been proven highly predictive importance of determining the level of expression of gene glutathione S-transferase P1 (GSTP1) in patients with neuroblastoma. Research conducted in 85 patients allowed to bring that high level expression of GSTP1 gene is a marker of unfavorable course of the disease, regardless of stage of disease, age and status of the gene MYCN. Thus, the rate of 2-year disease-free survival in patients with low expression of the gene GSTP1 was 61,0 %%, while in patients with high expression - only 34,0 % (p = 0,03). The newly prognostic criteria were treated 85 children diagnosed with neuroblastoma in age from 1 month to 15 years. The group risk include standard 33 patients (30.9 %), high - 52 children (69.1 %). As a result of the retrospective analysis of the disease and survival of children with neuroblastoma who received treatment in the pediatric oncology NCI in 2007-2012 gg., disease-free 5-year survival rate was in the group of standard risk 67.0 % in the high risk group - only 30.4%. The introduction of new prognostic criteria and treatment algorithms for diagnosis and treatment according intensification techniques developed in 2013- 2015's. In the research department of pediatric oncology NCI allowed in 85 children with neuroblastoma achieve 3-year overall survival 79.0 % standard risk group and 66.4 % in the high risk group. Disease-free 3-year survival was 65.1 % and 58.2 % respectively. Thus, the overall survival of patients at high risk (patients with very poor prognosis) almost doubled in the group of standard risk by 12%. Product Description popup.authors Іжовський Олексій Йожефович Білоконь Олег Вікторович Василишин Олег Володимирович Свергун Наталія Миколаївна Шайда Елен Вікторівна popup.nrat_date 2020-04-02 Close